Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

Similar articles for PubMed (Select 22512565)

1.

NK-1 receptor antagonists: a new generation of anticancer drugs.

Munoz M, Covenas R.

Mini Rev Med Chem. 2012 Jun;12(7):593-9. Review.

PMID:
22512565
2.

The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.

Munoz M, Covenas R, Esteban F, Redondo M.

J Biosci. 2015 Jun;40(2):441-63.

3.

Are antagonists at bradykinin 1 receptors promising analgesic drugs?

Schaible HG.

Eur J Pain. 2015 Jan;19(1):3-4. doi: 10.1002/ejp.591. No abstract available.

PMID:
25515093
4.

The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.

Muñoz M, González-Ortega A, Salinas-Martín MV, Carranza A, Garcia-Recio S, Almendro V, Coveñas R.

Int J Oncol. 2014 Oct;45(4):1658-72. doi: 10.3892/ijo.2014.2565. Epub 2014 Jul 28.

PMID:
25175857
5.

Involvement of substance P and the NK-1 receptor in human pathology.

Muñoz M, Coveñas R.

Amino Acids. 2014 Jul;46(7):1727-50. doi: 10.1007/s00726-014-1736-9. Epub 2014 Apr 6. Review.

PMID:
24705689
6.

Involvement of substance P and the NK-1 receptor in pancreatic cancer.

Muñoz M, Coveñas R.

World J Gastroenterol. 2014 Mar 7;20(9):2321-34. doi: 10.3748/wjg.v20.i9.2321. Review.

7.

Cancer progression and substance P.

Coveñas R, Muñoz M.

Histol Histopathol. 2014 Jul;29(7):881-90. Epub 2014 Feb 18. Review.

PMID:
24535838
9.

The NK-1 Receptor Antagonist L-732,138 Induces Apoptosis and Counteracts Substance P-Related Mitogenesis in Human Melanoma Cell Lines.

Muñoz M, Rosso M, González-Ortega A, Coveñas R.

Cancers (Basel). 2010 Apr 20;2(2):611-23. doi: 10.3390/cancers2020611.

10.

Immunolocalization of substance P and NK-1 receptor in Hofbauer cells in human normal placenta.

Muñoz M, Carranza A, Pavón A, Anderson G, Coveñas R.

Microsc Res Tech. 2013 Dec;76(12):1310-3. doi: 10.1002/jemt.22303. Epub 2013 Oct 24.

PMID:
24155270
11.

Involvement of substance P and the NK-1 receptor in cancer progression.

Muñoz M, Coveñas R.

Peptides. 2013 Oct;48:1-9. doi: 10.1016/j.peptides.2013.07.024. Epub 2013 Aug 7. Review.

PMID:
23933301
12.

Neurotransmitter substance P mediates pancreatic cancer perineural invasion via NK-1R in cancer cells.

Li X, Ma G, Ma Q, Li W, Liu J, Han L, Duan W, Xu Q, Liu H, Wang Z, Sun Q, Wang F, Wu E.

Mol Cancer Res. 2013 Mar;11(3):294-302. doi: 10.1158/1541-7786.MCR-12-0609. Epub 2013 Jan 23.

13.

The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists.

Muñoz M, González-Ortega A, Rosso M, Robles-Frias MJ, Carranza A, Salinas-Martín MV, Coveñas R.

Peptides. 2012 Dec;38(2):318-25. doi: 10.1016/j.peptides.2012.09.024. Epub 2012 Sep 28.

PMID:
23026680
14.

NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011.

Muñoz M, Martinez-Armesto J, Coveñas R.

Expert Opin Ther Pat. 2012 Jul;22(7):735-46. doi: 10.1517/13543776.2012.697153. Epub 2012 Jun 15. Review.

PMID:
22697287
15.

The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer.

Rosso M, Muñoz M, Berger M.

ScientificWorldJournal. 2012;2012:381434. doi: 10.1100/2012/381434. Epub 2012 Apr 1. Review. Erratum in: ScientificWorldJournal. 2012;2012:747912.

16.

Pharmacological mechanisms of 5-HT₃ and tachykinin NK₁ receptor antagonism to prevent chemotherapy-induced nausea and vomiting.

Rojas C, Slusher BS.

Eur J Pharmacol. 2012 Jun 5;684(1-3):1-7. doi: 10.1016/j.ejphar.2012.01.046. Epub 2012 Mar 9. Review.

PMID:
22425650
17.

Distribution and pharmacological characterization of primate NK-2 tachykinin receptor in the central nervous system of the rhesus monkey.

Nagano M, Oishi T, Suzuki H.

Neurosci Lett. 2011 Sep 26;503(1):23-6. doi: 10.1016/j.neulet.2011.07.057. Epub 2011 Aug 6.

PMID:
21855604
18.

Synergistic antiemetic interactions between serotonergic 5-HT3 and tachykininergic NK1-receptor antagonists in the least shrew (Cryptotis parva).

Darmani NA, Chebolu S, Amos B, Alkam T.

Pharmacol Biochem Behav. 2011 Oct;99(4):573-9. doi: 10.1016/j.pbb.2011.05.025. Epub 2011 Jun 13.

PMID:
21683089
19.

NK-1 as a melanoma target.

Muñoz M, Bernabeu-Wittel J, Coveñas R.

Expert Opin Ther Targets. 2011 Jul;15(7):889-97. doi: 10.1517/14728222.2011.586633. Epub 2011 May 19. Review.

PMID:
21592000
20.

NK-1 receptor antagonists: a new paradigm in pharmacological therapy.

Muñoz M, Coveñas R.

Curr Med Chem. 2011;18(12):1820-31. Review.

PMID:
21466470
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk